The treatment uses M1 LUMI bead technology. Interventional radiologists thread the beads into the blood vessels that lead to the tumor using a catheter. Because the beads are luminescent, physicians can see exactly where the beads are and make sure they are blocking the blood flow feeding the tumor, causing it to shrink.
The minimally invasive, radiopaque treatment is a “game-changer,” according to Edward Kim, MD, director of interventional oncology and associate professor of radiology and surgery at The Mount Sinai Hospital.
“In the past, we had no way to verify where the beads were placed in the blood vessels or whether they remained in the intended location over time. Now we can see the location, and adjust if a portion of the tumor has been missed while the patient is on the table without repeating the procedure,” said Dr. Kim. “This is what we call precision targeting of tumors.”
To learn more about the M1 LUMI bead technology, watch the video below.
More articles on cancer care:
Joe Biden names Greg Simon to lead cancer ‘moonshot’
The race to create liquid biopsies for cancer detection continues: 5 things to know
Tumor paint: How one physician is changing cancer treatment
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
